Wells Fargo & Company Lucid Diagnostics Inc. Call Options Transaction History
Wells Fargo & Company
- $468 Billion
- Q2 2025
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding LUCD
# of Institutions
69Shares Held
15.1MCall Options Held
0Put Options Held
0-
Vanguard Group Inc Valley Forge, PA4.13MShares$4.13 Million0.0% of portfolio
-
Masters Capital Management LLC Atlanta, GA2.73MShares$2.73 Million0.13% of portfolio
-
Geode Capital Management, LLC Boston, MA1.58MShares$1.58 Million0.0% of portfolio
-
Luminus Management LLC Houston, TX795KShares$794,8300.92% of portfolio
-
Alyeska Investment Group, L.P. Chicago, IL738KShares$738,2770.0% of portfolio
About Lucid Diagnostics Inc.
- Ticker LUCD
- Exchange NASDAQ
- Sector Healthcare
- Industry Medical Devices
- Shares Outstandng 38,568,500
- Market Cap $38.6M
- Description
- Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company. The company focuses on patients with gastroesophageal reflux disease, which is also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically highly lethal esophageal adenocarc...